Telix Highlights Neuro-Oncology Theranostics in Upcoming Webinar
Event summary
- Telix to host educational webinar on June 29, 2026 (EDT) focusing on neuro-oncology unmet needs and theranostics solutions.
- Clinical update by David N. Cade, MD, Telix Group Chief Medical Officer.
- Fireside chat featuring Nelleke Tolboom, MD (UMC Utrecht) and Josef Pichler, MD (Kepler University Hospital Linz).
- Q&A session with Richard Valeix, CEO of Telix Therapeutics.
The big picture
Telix's focus on neuro-oncology aligns with growing interest in precision medicine for aggressive brain cancers like glioma and glioblastoma. The webinar underscores the company's strategy to leverage theranostics—combining diagnostics and targeted therapy—to address significant unmet medical needs. This approach positions Telix within a niche but rapidly evolving segment of oncology, where radiopharmaceuticals are gaining traction as potential game-changers.
What we're watching
- Clinical Validation
- How Telix's neuro-oncology portfolio updates will impact physician adoption and therapeutic directions.
- Regulatory Pathways
- Whether the insights from European physicians will accelerate Telix's regulatory strategies in key markets.
- Market Positioning
- The pace at which Telix can differentiate itself in the competitive neuro-oncology theranostics space.